来源：生物谷 2014-02-12 14:34
2014年2月12日讯 /生物谷BIOON/ --新基（Celgene）2月11日宣布，抗癌药Pomalyst（pomalidomide胶囊）获加拿大卫生部批准，联合地塞米松（dexamethasone），用于既往经包括来那度胺（lenalidomide）和硼替佐米（bortezomib）在内至少2种治疗方案后病情恶化的多发性骨髓瘤（multiple myeloma）的治疗。在此之前，经传统疗法治疗失败的患者，临床治疗选择十分有限。临床试验中，对来那度胺或硼替佐米治疗不再响应的多发性骨髓瘤患者群体，pomalidomide已被证明能够提高总生存率（OS），并延长无进展生存期（PFS）。
此前，加拿大卫生部已授予Pomalyst优先审查资格，该药计划于2014年3月上市。
Pomalyst的获批，是基于关键性III期MM-003研究的结果。该项研究表明，与高剂量地塞米松治疗组相比，pomalidomide+低剂量地塞米治疗组总生存期（OS）得到显著改善（12.7个月 vs 8.1个月），疾病无进展生存期（PFS）显著延长（4.0个月 vs 1.9个月，p＜0.0001）。
关于Pomalyst：
Pomalyst（pomalidomide胶囊）由Celgene公司开发，该药是一种口服免疫调节药物，通过对耐药性骨髓瘤细胞的靶向作用，Pomalyst能够抑制细胞的生长、诱导细胞凋亡，同时增强机体自身对肿瘤的免疫反应。Pomalyst于2013年2月获FDA批准，用于其它癌症药物治疗后病情仍有进展的多发性骨髓瘤患者的治疗。
此次获批，标志着加拿大批准的第3种多发性骨髓瘤口服治疗药物。（生物谷Bioon.com）
英文原文：Celgene: Health Canada Approves Pomalyst For Patients With Multiple Myeloma
2/11/2014 6:44 AM ET
Drug maker Celgene Corp. (CELG: Quote) said Tuesday that Health Canada has approved Pomalyst oral therapy (pomalidomide capsules) in combination with dexamethasone, for patients with multiple myeloma for whom both lenalidomide and bortezomib have failed, who have received at least two prior treatment regimens and have demonstrated disease progression on their last regimen. The company expects that Pomalyst will be commercially available in March 2014.
The company said Treatment with Pomalyst has been shown to improve rates of overall survival and extend progression-free survival in patients who no longer respond to lenalidomide or bortezomib.
Pomalyst received priority review status by Health Canada due to the high unmet medical need that exists and the clinical value that the treatment brings to patients and physicians.
The Health Canada approval of POMALYST was based on the MM-003 pivotal study, which was published in The Lancet Oncology in October 2013. The MM-003 pivotal study demonstrated significantly improved median progression-free survival of four months (p<0.001) for patients with relapsed refractory multiple myeloma who were treated with pomalidomide plus low-dose dexamethasone, compared with 1.9 months for those treated with high-dose dexamethasone only.
Pomalyst (pomalidomide capsules) is an oral immunomodulatory drug. Through its targeted action on treatment-resistant myeloma cells, Pomalyst inhibits tumour cell growth, triggers cell death and enhances the body's own immune response to the tumour. Pomalyst was discovered and developed by Celgene, and represents the third novel oral treatment for multiple myeloma to be approved in Canada.
多发性骨髓瘤新方案！强生Darzalex分割剂量方案获欧盟批准，将赋予更大的治疗灵活性
APP专享
海洋来源抗癌药Aplidin获批：首个新一类多发性骨髓瘤疗法
APP专享
深圳普瑞金公布CART-BCMA疗法研究结果，在治疗复发/难治多发性骨髓瘤中展示显著疗效
APP专享
CD19与BCMA CAR-T联合，或利于高危多发性骨髓瘤的治疗并克服肿瘤逃逸
APP专享
Celgene和bluebird共同宣布：针对多发性骨髓瘤的BCMA CAR-T进入二期临床试验
APP专享
BCMA靶点新药！西雅图遗传学糖工程新型抗体SEA-BCMA治疗多发性骨髓瘤进入临床开发
APP专享
治疗多发性骨髓瘤 BMS创新免疫组合疗法扩展适应症
APP专享
多发性骨髓瘤新药！百时美免疫刺激疗法Empliciti三药方案获美国FDA批准
APP专享
Celgene淋巴瘤疗法优势突出 显著改善PFS
APP专享
多发性骨髓瘤疗法Darzalex 3期结果积极
APP专享
空中讲坛 Webinar
